November 16, 2018 06:57 AM ESTUpdated 09:23 AM
Financing
Startups

With ra­dio­ther­a­py en vogue, Bel­gian start­up nabs near­ly $42M in Se­ries A fund­ing

ENDPOINTS

In­ter­est in tar­get­ed ra­di­a­tion treat­ments was buoyed last month with No­var­tis’ $NVS $2.1 bil­lion bet on En­do­cyte that put the spot­light on a decades …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk CEO to step down, time­line for suc­ces­sor un­known

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

It's been three months with­out a biotech IPO

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

A service from the Financial Times